Mycoplasma gallisepticum (MG) is a bacterial pathogen that causes production losses in layer chickens. To combat MG, multiage layer facilities vaccinate pullets by either spray or eye-drop vaccination. The objective in this study was to evaluate the use of in ovo vaccination as a potential alternative for MG vaccination. Layer embryos at 18 d of incubation were either not-injected (control), or were hand-injected with either commercial Marek's disease vaccine diluent alone or with a high, medium, low, or very low dosage of a live attenuated strain F (FMG) vaccine suspended in the commercial diluent. Hatch success and residual egg embryonic mortality were determined after 23 d of incubation. Six hatched chicks per treatment were swabbed for the detection of FMG at 4 different sites (trachea, mouth and esophagus, yolk sac membrane, and the lumen of the duodenal loop) via real-time PCR. Embryos were found to be administered 10 6 CFU per dose in the high treatment, 10 4 CFU/dose in the medium treatment, 10 2 CFU/dose in the low treatment, and between 5.06 and 5.93 CFU/dose in the very low treatment. Hatch of embryonated eggs was decreased by the medium and high doses (P = 0.02). These embryos died while pipping. No FMG was detected in the control and diluent-injected chicks. In the FMG treatments, FMG was found in all sites and dosages, with a greater number of positive chicks found in the higher FMG dosage treatments. These findings indicate the potential practicality of vaccinating layer embryos with FMG by in ovo injection based on the observed hatch success at lower dosages. Also, once injected into the amnion, the bacteria are present in the upper respiratory and gastrointestinal tracts as well the yolk sac membrane and the small intestine of hatchlings. Future research will need to ascertain the effects of FMG administered by in ovo injection on posthatch immunity and mortality.
INTRODUCTION
Mycoplasma gallisepticum (MG) infections are considered an endemic production issue on multi-age layer complexes causing a reduction in egg production by approximately 10 to 15% (Carpenter et al., 1981; Lin and Kleven, 1982; Evans et al., 2005; Ley, 2008; Hy-Line International, 2013) . To combat egg losses, pullets are typically vaccinated against MG between 8 and 18 wk of age (before the start of egg production) utilizing an oil emulsion bacterin or a live attenuated vaccine (Levisohn and Kleven, 1981; Whithear, 1996; Evans et al., 2005) . Live attenuated vaccines are delivered by either a spray or eye-drop method, and bacterins are administered subcutaneously (Whithear, 1996) . Thus, these methods can be labor intensive.
In ovo vaccination has been a successful technique in eliminating the need to manually vaccinate broilers posthatch for Marek's disease (Sharma and Burmester, 1982; Johnston et al., 1997; Ricks et al., 1999) , and the technique has additionally proven effective for other viral poultry diseases (Sharma, 1985; Wakenell and Sharma, 1986; Stone et al., 1997; Ricks et al., 1999; Rautenschlein and Haase, 2005; Mast et al., 2006; Tarpey et al., 2006; Tarpey and Huggins, 2007; Toro 3879 et al., 2007; Johnson et al., 2010; Cai et al., 2011) . In ovo vaccination of a bacterial organism, however, has not been adequately investigated. Only a few reports are available that have evaluated the potential of in ovo vaccination against Campylobacter and Salmonella (Coloe et al., 1994; Noor et al., 1995) , with the majority of published bacterial in ovo research pertaining to the in ovo administration of probiotic bacteria (Meijerhof and Hulet; Cox et al., 1992; Edens et al., 1997; Yamawaki et al., 2013; De Oliveira et al., 2014) .
The initial report providing evidence for the success of vaccinating birds against MG was accomplished utilizing live attenuated strain F MG (FMG) (Levisohn and Kleven, 1981) . Vaccinating layer chickens with FMG posthatch has been shown to provide adequate protection against field strains of MG for the life of the laying hen, with an ability to "displace" field strains in the trachea (Cummings and Kleven, 1986; Kleven et al., 1998; Hy-Line International, 2013) . The FMG vaccine has been found to be more protective, yet more virulent, in comparison to the other available live MG vaccine strains (6/85 and ts-11; Abd-El-Motelib and Kleven, 1993; Kleven et al., 1998) . Thus, the purpose of this study was to investigate the potential of employing in ovo injection for the administration of the FMG vaccine to layers which may serve as a viable and potential labor saving vaccination option for the layer industry.
MATERIALS AND METHODS

Egg Incubation
Three hundred and sixteen fertile Hy-Line W-36 layer eggs were obtained from a 34-week-old MG-clean commercial breeder flock (National Poultry Improvement Plan, 2014) and incubated in a calibrated NOM 45 NatureForm Incubator (NatureForm Incubator Company, Jacksonville, Florida) set at 37.5
• C and 53% RH (29.0
• C wet bulb) for the first 18 d of incubation (DOI).
Treatments
On 18 DOI, all live embryonated eggs (determined live via candling) were randomly assigned to hatching baskets with 3 replicate trays for each of 6 treatments (n = 16 live embryonated eggs in each basket), and block randomized according to hatcher dimensions and capacity. The 6 treatments were designated as follows: non-injected control eggs, control eggs injected with Poulvac Marek's disease vaccine diluent (Zoetis, Exton, PA), and eggs injected with high, medium, low, and very low doses of Poulvac Myco F vaccine (Zoetis, New York, NY) resuspended and diluted in Poulvac Marek's disease vaccine diluent. The high dose was taken directly from the vaccine vial of the manufacturer that was resuspended in 50 mL of Marek's disease vaccine diluent. The medium dose was a dilution of 10 -2 , the low dose was a dilution of 10 -4 , and the very low dose was a dilution of 10 -6 of the original resuspended vaccine vial.
All treatments were injected with a total 50 μL volume following the procedures of the "Manual in ovo Vaccination Guide" by Embrex Inc. (2002) . The treatments were injected in order from the lowest dose to the highest dose to limit any potential drastic changes in bacteria counts while the vaccines were awaiting injection as well as limiting any unwanted transmission of bacteria from the higher to lower dosages. The 1X vaccine from the vaccine vial (high dose) was plated prior to and after injection of all eggs (2 plates per time period). The post-injection vaccine remained at room temperature during the injections to determine possible changes in bacterial concentration during the injection process.
Nine live embryonated eggs were injected with Coomassie brilliant blue R-250 dye (Genlantis, San Diego, CA) and immediately euthanized. The eggs were opened to determine the location of the dye and the stage of the embryo (Avakian, 2006) .
Data Collection
All posthatch procedures were approved by the USDA-ARS Institutional Animal Care and Use Committee (Mississippi State, MS). The hatch was monitored for completion and all hatched chicks were counted and all residue eggs were opened to confirm a late stage of embryonic death. The chicks and their yolk sacs were individually weighed immediately after euthanasia via carbon dioxide. The yolk sacs were dried at 65
• C for 3 d and then reweighed to determine yolk moisture content.
Detection of FMG Presence
Six chicks from each treatment (2 per hatch basket) were swabbed using sterile swabs moistened in phosphate-buffered saline (PBS) at 4 locations to detect the presence of FMG. The locations included inside the mouth and down the esophagus, down the trachea through the larynx, on the surface of the yolk sac membrane, and inside the duodenal loop of the small intestine leading toward the jejunum. Each swab sample was suspended in 110 μL of PBS. Any bacterial DNA in the swab sample was extracted using the Qiagen BioSprint 96 One-For-All Vet Kit (Qiagen, Valencia, CA). Two replicates per sample were run using a 7500 Fast Real Time PCR System (Applied Biosystems, Foster City, CA) using FMG strain specific primers and probe designed by Raviv et al. (2008) . Primers were diluted to a 0.5 μM concentration and the probe used was a 0.1 μM concentration. Each total 25 μL polymerase chain reaction (PCR) volume consisted of 2.5 μL of the forward primer (5 GTTCAAGAACCAACTCAACCA 3 ), 2.5 μL of the reverse primer (5 GATTAAGAC-CGAATTGTGGATTG 3 ), 2.5 μL of the probe (5 CAACCAGGATTTAATCAACCTCAG 3 ), 12.5 μL of Taqman Universal Master Mix (Applied Biosystems, Foster City, CA), 2.5 μL solution of extracted DNA, and sterile water. The cycling parameters were 95
• C for 15 min and 40 cycles at 94
• C for 15 s and 61
• C for 1 min. Sterile water was used as a negative control, and a previously known FMG DNA sample was used as a positive control for the determination of the standard curve at a dilution of 10 -1 , 10 -2 , 10 -3 , and 10 -4 . Since there was variation in surface area of the swabbed area of each bird, results were determined on a qualitative basis (positive or negative for FMG presence).
Statistical Analysis
Hatch data, and chick and yolk weights and percentages were analyzed as a general linear model using SAS Version 9.3 (SAS Institute, 2014) to evaluate differences between treatments and potential location effects within the incubator. Percentage hatch of live embryonated eggs was analyzed using the hatch basket as the experimental unit, and chick and yolk weights and percentages were analyzed on an individual chick or yolk basis. Significance was based on P ≤ 0.05 and differences were determined using Fisher's least significant difference.
RESULTS AND DISCUSSION
The time elapsed from resuspension of the vaccine to the conclusion of the injection process was approximately 1.5 h. The bacterial loss from the beginning to the conclusion of the injection process was negligible. Mean plate counts of the 10 -4 dilution were 237 CFU/20 μL and at the same dilution, mean plate counts of the vaccine held at room temperature through the injection process were 202.5 CFU/20 μL. These counts indicated that the bacterial delivery in the high, medium, low, and very low dose treatments were in the concentration ranges of 5.06 to 5.93 × 10 6 , 5.06 to 5.93 × 10 4 , 5.06 to 5.93 × 10 2 , and 5.06 to 5.93 CFU per dose, respectively.
All 9 embryonated eggs injected with dye (9.4% of all live embryonated eggs) were at stage 2 of embryonic development, with dye in the amniotic sac surrounding the embryo. These embryos had not yet pipped internally and were oriented with their heads positioned between their legs. The amniotic sac injection may have provided FMG access to colonize the trachea (Cummings and Kleven, 1986; Kleven et al., 1998) .
The chicks were removed from the incubator at approximately 23 DOI to ensure that all possible chicks emerged from their shells. Live external pips were noted in the high treatment baskets at 22 DOI. Extra incubation time was allotted since the focus of this trial was to 3 Diluent injected embryos were injected with Marek's disease vaccine diluent, which was also used to dilute a strain F Mycoplasma gallisepticum (FMG) vaccine (Poulvac Myco F) as follows: Very-low dose FMG injection was a 10 -6 dilution of the original resuspended vaccine vial; low dose (10 -4 dilution of the original resuspended vaccine vial); medium dose (10 -2 dilution of the original resuspended vaccine vial); high dose (taken from the resuspended vaccine vial).
4 Dead chicks were chicks that had successfully hatched and were found dead in the hatcher. 5 Unhatched eggs which contained a dead late stage embryo or a chick that had pipped through the eggshell and was still alive (live pip) but had not emerged from the egg or pipped and found dead (dead pip).
a-c Means with differing superscripts within a column are significantly different (P < 0.05) determined by Fisher's least significant difference. determine embryo survival to hatch. As seen in Table 1 , those live external pips became dead external pips.
Percentage hatch of live embryonated eggs (Table 1 ) decreased with increasing bacterial dosage (P = 0.02). At the highest FMG vaccine dosage (10 6 organisms), approximately 40% of the layer embryos were inhibited from hatching. Of the embryos that failed to hatch (as observed by the hatchery residue; Table 1 ), only the percentage of dead pipped mortalities (embryos that had survived to externally pip through the eggshell but died before fully emerging from the eggshell) differed by treatment (P = 0.003) with greater percentages in the medium-and high-dose groups.
Past researchers injected MG into embryonated chicken eggs with the purpose to rate the pathogenicity of various MG strains at different passage levels (Yoder, Jr. and Hofstad, 1964; Roberts and Olesiuk, 1966; Jordan, 1973, 1976; Levisohn et al., 1985; Akhtar et al., 1991) . However, only 2 of these studies have reported the hatch results of embryos that were injected with MG (Roberts and Olesiuk, 1966; Power and Jordan, 1976) . Power and Jordan (1976) injected MG into the yolk sacs of specific pathogenfree embryos at 18 DOI, and although they did not report the exact hatch results, it is clear that some embryos survived to hatch, as they were able to rear birds for further posthatch evaluations. Roberts and Olesiuk (1966) injected FMG at various passage levels and dilutions ranging from 10 -3 to 10 -8 of the starting bacterial culture (10 8 colony forming units (CFU) per mL) into the yolk sacs of embryonated chicken eggs at 7 DOI. The largest percentage hatch recorded (54% of inoculated embryos) was at the highest passage level (63) and the largest dilution (10 -8 ). They noted that the highest level of mortality occurred in embryos that were injected with FMG that had undergone less than 34 passages. Furthermore, lower dilutions were found to cause embryonic death earlier (4 to 8 d after injection), while embryos that received higher dilutions died later as dead pips. Dead pips also made up a greater percentage of embryonic mortalities in groups that received FMG that underwent higher passage rates.
The hatchability results of the present study are much higher than those of Roberts and Olesiuk (1966) . The present study injections were on 18 DOI instead of 7 DOI and were injected into the amnion instead of the yolk. The FMG vaccine utilized in this current study (Poulvac Myco F Zoetis, New York, New York) is also potentially a less-virulent/higher passaged FMG than that used by Roberts and Olesiuk (1966) . Our findings agree, though, that the lower dosages of the live FMG resulted in a better hatch than the higher FMG dosages (Table 1) .
Total chick BW (P = 0.26), yolk-free chick BW (P = 0.27), wet (P = 0.49) and dry (P = 0.21) yolk weights and wet (P = 0.56) and dry (P = 0.26) yolks as percentages of initial chick BW were not different between the 6 treatments. The percentage of water in the yolk sac contents differed between treatments (P < 0.0001, see Figure 1 ) with a decreased percentage water in the yolk sac contents of the non-injected treatment group. Greater percentage water in the yolk sac contents was found in the higher dosage groups. This may be due to a general observation that the non-injected chicks hatched faster than the other treatments and had more time to lose water in the hatcher than did the chicks from the injected treatments. Nevertheless, a hatch pattern of the different treatment groups was not monitored and would be needed to confirm this observation. Additionally, this difference in percentage water in the yolk sac may be more pronounced since the chicks were removed from the incubator at 23 DOI, which is 30 h longer than the ideal incubation duration of 21 d and 18 h for Hy-Line W-36 chicks . The bacterial challenge to the embryo may have slowed the hatching process and thus diminished the exposure time of the fully emerged chick to the drying effects of the hatcher.
There were no location effects within the incubator for percentage hatch of live embryonated eggs, any of the residue egg categories, chick or yolk weights or percentage of water in the yolk sac contents (all P > 0.30).
A total of 5 chicks were observed to exhibit extended neck breathing. There were 2 chicks in one of the medium-dose baskets, and one chick in each of the high-dose baskets that exhibited this behavior. Colonization of a large number of FMG organisms in the trachea and lungs that were introduced in the medium and high dosages may have caused the respiratory distress in those birds. Tracheal colonization has been observed in work conducted on adult chickens by Levisohn et al. (1983) . Further work would be needed to determine if these chicks would recover from these effects during posthatch rearing or if they would succumb to the bacterial load. A decline in oxygen intake in association with this respiratory distress may have contributed to the potential delay in hatch time.
The PCR results from the swab samples taken at the 4 body sites within 6 hatched chicks per treatment are shown in Figure 2 . No chicks in the control or diluent-injected treatments were positive for FMG at any of the swabbed sites. It is interesting to note that -6 dilution, low dose was a 10 -4 dilution, and the medium dose was a 10 -2 dilution. The high dose was taken directly from the original resuspended vaccine vial.
although these treatments were interspersed within the same hatcher, no FMG was detectable in the interior of the control birds. Approximately half of the tested chicks in the very low dose group possessed FMG in the mouth and esophagus, trachea, and yolk sac membrane, and one very low dose chick tested positive for FMG in the duodenal loop. The presence of FMG was also detected in all 4 sites of chicks in the other treatments, with more positive samples being generally detected as the dosages were increased. The site with the majority of positive samples was the trachea. This was followed by the mouth and esophagus, then by the yolk sac membrane. The presence of FMG was least detected in the duodenal loop although other research has also reported findings of in ovo injected substances reaching the duodenal loop of embryos (Jochemsen and Jeurissen, 2002) . The finding that more chicks tested positive for FMG in the trachea and mouth and esophagus supports the idea that the embryo swallows and aspirates the contents of the amnion. This is confirmed in the current study, particularly since the dye-injected chicks were all injected in the amnion. Injections into the amnion also bathe the feathers of the embryo, as seen by the presence of dye in the feathers of the dyeinjected embryos. This injection location also has the potential to allow for bacterial transmission between hatch mates once the chick emerges from the shell. However, if any horizontal transmission occurred at hatch in the present study, FMG was not detectable in any of the sites of the control and diluent-injected chicks. It is possible, due to the sensitivity of our PCR reaction, that the transmission of smaller amounts of bacteria within the hatcher occurred via the down and feathers without detection. Future research should be conducted raising these birds to allow for bacterial growth to reach detectable levels to determine if horizontal transmission could occur within the hatcher through the circulation of infected down and feathers.
This initial trial showed that layer embryos from MGclean breeders are able to survive to hatch successfully after being administered a live attenuated FMG vaccine at 18 DOI. The results also show a higher layer embryo mortality and a potential delay in time of hatch in response to higher amounts of injected bacteria, although the high-dose level only caused 40% embryonic mortality. Future work will consider posthatch survival and immune responses of FMG in ovo-vaccinated birds.
